Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 on ClinicalTrials.gov · last registry update 2026-09-02
Finished 20 January 2026, after enrolling 114 people. Primary outcome, as filed: The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 3 times since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Mostafa Bahaa
- Sponsor type
- Other
- Enrollment
- 114
- Started
- 2025-01-20
- Primary completion
- 2026-01-20 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-02 | Reporting date moved | 2027-09-20 → 2026-01-20 20 months earlier |
| 2026-09-02 | Status changed | RECRUITING → COMPLETED |
| 2026-09-02 | Enrollment changed | 105 → 114 (+9) participants |
Primary outcome
The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment.
Conditions studied
Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.